EyePoint licenses inflammation drug to Atlanta firm for $82.5M

EyePoint Pharmaceuticals Inc. is selling the rights to one of its eye disease drugs as it aims to be "a pure-play drug development company."

Source: bizjournals.com Health Care:Physician Practices headlines - May 18, 2023 Category: American Health Authors: Rowan Walrath Source Type: news